Senior Director, Manufacturing Sciences & Technologies
ADC Therapeutics
Summary
The Senior Director of Manufacturing Sciences & Technologies (MSAT) is a senior technical leader responsible for end-to-end process ownership, technical oversight, and lifecycle management of drug substance intermediates, ADC drug substance, and ADC drug product manufactured through a global network of external CDMOs.
Job description
Job Summary
The Senior Director of Manufacturing Sciences & Technologies (MSAT) is a senior technical leader responsible for end-to-end process ownership, technical oversight, and lifecycle management of drug substance intermediates, ADC drug substance, and ADC drug product manufactured through a global network of external CDMOs.
This role ensures robust, scalable, and compliant manufacturing processes that support commercial manufacturing, process development projects and clinical development, while serving as the senior-level technical support for internal Production Management Teams and external manufacturing partners.
The position plays a critical role in process validation, technology transfer, continued process verification (CPV), change management, technical and regulatory support across antibody, linker-payload, conjugation, formulation, fill/finish, and packaging operations.
This position reports to the Vice President, Global Supply & Operations. The role is remote based, with a preference for candidates located on the U.S. East Coast.
What You'll Do
MSAT Strategy and Leadership
- Lead and develop the MSAT function covering ADC end-to-end manufacturing across clinical and commercial stages.
- Define MSAT strategy for external manufacturing aligned with corporate objectives.
- Develop and mentor a high-performing MSAT team with deep expertise in biologics, highly potent payloads, and aseptic operations.
- Serve as a key member of the Operations Management Team to contribute to long-term supply, risk mitigation, and operational excellence initiatives.
Manufacturing Process Oversight (External Manufacturing)
- Accountable for overall manufacturing process stewardship, ensure robust process knowledge management and align process understanding within ADCT and at the CDMO partners.
- Partner with Quality and Supply Chain to ensure ADCT's Production Management Teams effectively interface and manage CDMO performance.
- Oversee and guide: MSAT activities at CDMOs, process characterization, validation (PPQ), process monitoring and CPV programs.
- Ensure consistent process understanding and control across global manufacturing partners.
- Drive effective issue resolution for manufacturing deviations, CAPAs, and change requests.
- Support CDMO selection, technical due diligence, and onboarding for new manufacturing partners.
Process Lifecycle Management
- Provide scientific and technical oversight across the full ADC manufacturing lifecycle.
- Assess and implement post approval changes, comparability strategies, and process optimization initiatives.
- Oversee and endorse process improvements to enhance process robustness, yield, cost, and supply reliability.
Regulatory & Quality Support
- Serve as the senior-level accountable MSAT person for regulatory submissions and inspections, including INDs, BLAs, MAAs, supplements to these filings.
- Author, review, and approve CMC regulatory sections and responses.
- Support health authority inspections and technical audits of CDMOs.
- Partner closely with Quality to ensure compliance with cGMP, ICH, and global regulatory expectations.
- Ensure sound scientific justifications for process control strategies, specifications, and lifecycle changes.
Cross Functional Collaboration
- Collaborate closely with Quality Assurance, Quality Control, Supply Chain and CMC Regulatory
- Provide MSAT input into development programs, commercial readiness, and long range supply planning.
- Participate in internal governance forums, change control boards, and technical review committees.
Risk Management & Continuous Improvement
- Establish and track critical process parameters (CPPs) and CPV metrics.
- Proactively identify and mitigate technical and operational risks within ADC Therapeutics' external manufacturing network.
- Drive lessons learned, standardization, and continuous improvement across CDMOs and Production Management Teams.
Requirements
- Advanced degree (MS or PhD) in Biochemistry, Chemical Engineering, Biotechnology, or related field; BS with significant industry experience considered
- 12+ years of relevant experience including biologics manufacturing, CMC operations, and CDMO management
- Extensive experience in commercial GMP manufacturing operations, process validation, CPV, and regulatory submission preparation
- Strong scientific problem-solving and root-cause analysis skills
- Proven ability to lead through influence in external or remote environments
- Excellent communication skills for executive, regulatory, and partner interfaces
- Strategic thinker with strong execution focus
- Comfortable operating in a fast-paced, commercial-stage organization
- Deep knowledge of relevant bioconjugate technologies is preferred (antibody, high potency linker-payload, conjugation, aseptic fill and lyophilization)
- Strong track record of building and leading technical and cross-functional teams
- Visionary leadership with a strategic mindset
- High standards of excellence, urgency, and accountability
- Collaborative, team-oriented approach
- Strong organizational and critical thinking skills
- Ability to mentor, influence, and drive change across a remote organization
- Domestic and international travel up to 20%, primarily to CDMOs
Company overview
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs), specializing in oncology therapeutics. Founded in 2011 and headquartered in Lausanne, Switzerland with operations in New Jersey, the company focuses on developing highly potent and targeted ADCs for the treatment of hematological cancers and solid tumors. Their flagship product, ZYNLONTA® (loncastuximab tesirine-lpyl), is a CD19-directed ADC that received accelerated FDA approval and conditional European Commission approval for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company leverages specialized capabilities spanning clinical development, manufacturing, and commercialization, with a proven track record that includes an approved and marketed product. ADC Therapeutics maintains a global team of over 300 employees and operates with a flat organizational structure that encourages collaboration and innovation. Beyond ZYNLONTA, the company is advancing IND-enabling activities for a next-generation PSMA-targeting ADC and exploring combination therapies and earlier lines of treatment. Their mission centers on transforming cancer treatment paradigms through targeted ADC technology and bringing novel therapeutic options to patients worldwide.